Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
← catalyst calendarNCT05599412 · readout in 530 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
600estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-22 | actual | When the study began enrolling |
| Primary completion | 2028-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic ALK+ Non Small Cell Lung Cancer
Intervention
- Drug: Lorviqua
Primary outcome
what the primary-completion date above is the date OFIncidence of the adverse events from baseline
measured Up to 2 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed